A61K 31/547
Spiro-condensed or forming part of bridged ring systems
Official title: spiro-condensed or forming part of bridged ring systems
A61K31/547 (Spiro-condensed or forming part of bridged ring systems) appears on 17 US grants and 37 published applications in this corpus.
Search patents in A61K- Granted patents
- 17
- Published applications
- 37
- Assignees
- 23
- Inventors
- 129
- Latest grant
- 3 Sep 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 3 |
| 2014 | 3 | 1 |
| 2015 | 0 | 2 |
| 2016 | 3 | 4 |
| 2017 | 2 | 2 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 2 | 2 |
| 2021 | 1 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 1 | 2 |
| 2025 | 0 | 3 |
| 2026 | 0 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Heterocyclic degronimers for target protein degradation3 Sep 2024US 12,076,405 B2C4 Therapeutics, Inc.
- Sulfur-containing polycyclic-hydroxypyridone carboxamide analog against HIV21 Jun 2022US 11,365,207 B2
- Heterocyclic degronimers for target protein degradation2 Feb 2021US 10,905,768 B1C4 Therapeutics, Inc.
- Heterocyclic degronimers for target protein degradation12 May 2020US 10,646,575 B2C4 Therapeutics, Inc.
- Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance7 Apr 2020US 10,612,095 B2Dana-Farber Cancer Institute, Inc.
- Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same1 Oct 2026US 2026/0297073 A1Chong Kun Dang Pharmaceutical Corp.
- Macrocyclic compounds, preparation method therefor, and use thereof13 Aug 2026US 2026/0234165 A1Genfleet Therapeutics (Shanghai) Inc.
- Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same7 May 2026US 2026/0125370 A1Chong Kun Dang Pharmaceutical Corp.
- Compositions and methods for inhibition of kras7 May 2026US 2026/0125386 A1Lawrence Livermore National Security, LLC
- Compositions and methods for inhibition of kras12 Feb 2026US 2026/0042764 A1Lawrence Livermore National Security, LLC
Most cited
By later US patents
- Methods of treating cytokine mediated diseases53US 7,211,575 B2Boehringer Ingelheim Pharmaceuticals, Inc. · 2007
- Heterocyclic degronimers for target protein degradation34US 10,646,575 B2C4 Therapeutics, Inc. · 2020
- Heterocyclic degronimers for target protein degradation33US 10,905,768 B1C4 Therapeutics, Inc. · 2021
- Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof4US 8,828,994 B2Sanofi · 2014
- Dual NK1/NK3 receptor antagonists3US 7,939,533 B2Hoffmann-La Roche Inc. · 2011